Skip to main content
SpringerLink
Log in

Target Volume Delineation Guidelines in Bladder Cancer

  • Chapter
  • First Online:
Principles and Practice of Urooncology

  • 1281 Accesses

Abstract

The use of radiotherapy (RT) in the treatment of bladder cancer has been decreasing through the years. There is no role of RT in carcinoma in situ and Ta and Tl tumors. However, irradiation may have a role in high-grade or recurrent T1 lesions. There is no prospective randomized trial comparing surgery with RT in muscle-invasive bladder cancer. In T2–T4a disease without lymph node (LN) involvement, RT can be combined with concurrent chemotherapy in medically fit patients. However, there is no rationale of RT in patients with LN or distant metastasis except for palliative reasons. The gross tumor volume (GTV), clinical target volume (CTV), planning target volume (PTV), and organs at risk (OAR) should be delineated separately in each slice based on the recommendations in the International Commission on Radiation Units and Measurements (ICRU) reports 50 and 62. The only delineation guideline for the RT in bladder cancer has been reported by the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group .

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. van der Werf-Messing B, Hop WC. Carcinoma of the urinary bladder (category T1NxM0) treated either by radium implant or by transurethral resection only. Int J Radiat Oncol Biol Phys. 1981;7(3):299–303.

    Article  PubMed  Google Scholar 

  2. Van der Steen-Banasik EM, Visser AG, Reinders JG, Heijbroek RP, Idema JG, Janssen TG, et al. Saving bladders with brachytherapy: implantation technique and results. Int J Radiat Oncol Biol Phys. 2002;53(3):622–9.

    Article  PubMed  Google Scholar 

  3. Rodel C, Grabenbauer GG, Kuhn R, Dunst J, Papadopoulos T, Schrott KM, et al. Invasive bladder cancer: organ preservation by radiochemotherapy. Front Radiat Ther Oncol. 2002;36:118–30.

    Article  CAS  PubMed  Google Scholar 

  4. Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 2006;24(15):2318–24.

    Article  PubMed  Google Scholar 

  5. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14(11):2901–7.

    Article  CAS  PubMed  Google Scholar 

  6. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28(33):4912–8.

    Article  PubMed  Google Scholar 

  7. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7.

    Article  PubMed  Google Scholar 

  8. Mak RH, Zietman AL, Heney NM, Kaufman DS, Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int. 2008;102(9 Pt B):1345–53.

    Article  PubMed  Google Scholar 

  9. Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5(6):471–6.

    Article  CAS  PubMed  Google Scholar 

  10. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19(3):666–75.

    Article  CAS  PubMed  Google Scholar 

  11. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001;165(4):1111–6.

    Article  CAS  PubMed  Google Scholar 

  12. Efstathiou JA, Zietman A Coen JJ, Shipley WU. Bladder cancer. In: Gunderson LL, Tepper JE Clinical radiation oncology. 3rd ed. China: Elsevier Saunders; 2012. 1099–1123.

    Chapter  Google Scholar 

  13. Measurements. ICoRUa. ICRU Report 50: prescribing, recording and reporting photon beam therapy. Bethesda, Maryland, USA; 1993.

    Google Scholar 

  14. Measurements. ICoRUa. ICRU Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, Maryland, USA; 1999.

    Google Scholar 

  15. Hindson BR, Turner SL, Millar JL, Foroudi F, Gogna NK, Skala M, et al. Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. J Med Imaging Radiat Oncol. 2012;56(1):18–30.

    Article  PubMed  Google Scholar 

  16. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–31.

    Article  PubMed  Google Scholar 

  17. Foroudi F, Wong J, Haworth A, Baille A, McAlpine J, Rolfo A, et al. Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography. J Med Imaging Radiat Oncol. 2009;53(2):226–33.

    Article  CAS  PubMed  Google Scholar 

  18. Richards KA, Parks GE, Badlani GH, Kader AK, Hemal AK, Pettus JA. Developing selection criteria for prostate-sparing cystectomy: a review of cystoprostatectomy specimens. Urology. 2010;75(5):1116–20.

    Article  PubMed  Google Scholar 

  19. Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37(6):726–34.

    Article  PubMed  Google Scholar 

  20. Stein JP, Penson DF, SD W, Skinner DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol. 2007;178(3 Pt 1):756–60.

    Article  PubMed  Google Scholar 

  21. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008;26(1):121–6.

    Article  PubMed  Google Scholar 

  22. Buscarini M, Josephson DY, Stein JP. Lymphadenectomy in bladder cancer: a review. Urol Int. 2007;79(3):191–9.

    Article  PubMed  Google Scholar 

  23. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9.

    Article  PubMed  Google Scholar 

  24. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006;107(10):2368–74.

    Article  PubMed  Google Scholar 

  25. Sengelov L, von der Maase H. Radiotherapy in bladder cancer. Radiother Oncol. 1999;52(1):1–14.

    Article  CAS  PubMed  Google Scholar 

  26. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.

    Article  CAS  PubMed  Google Scholar 

  27. Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457–62.

    Article  PubMed  Google Scholar 

  28. Turner SL, Swindell R, Bowl N, Marrs J, Brookes B, Read G, et al. Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int J Radiat Oncol Biol Phys. 1997;39(2):355–60.

    Article  CAS  PubMed  Google Scholar 

  29. Harris SJ, Buchanan RB. An audit and evaluation of bladder movements during radical radiotherapy. Clin Oncol (R Coll Radiol). 1998;10(4):262–4.

    Article  CAS  Google Scholar 

  30. Sur RK, Clinkard J, Jones WG, Taylor RE, Close HJ, Chaturvedi A, et al. Changes in target volume during radiotherapy treatment of invasive bladder carcinoma. Clin Oncol (R Coll Radiol). 1993;5(1):30–3.

    Article  CAS  Google Scholar 

  31. Graham J, Gee A, Hilton S, et al. Geometric uncertainties in radiotherapy of the prostate and bladder. In:Geometric uncertainties in radiotherapy. London: British Institute of Radiology; 2003.

    Google Scholar 

  32. Meijer GJ, Rasch C, Remeijer P, Lebesque JV. Three-dimensional analysis of delineation errors, setup errors, and organ motion during radiotherapy of bladder cancer. Int J Radiat Oncol Biol Phys. 2003;55(5):1277–87.

    Article  PubMed  Google Scholar 

  33. Roof KS, Mazal A, Sarkar S, et al. A three-dimensional CT based analysis of inter-fraction bladder motion during radiotherapeutic treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 2004;60:S430.

    Article  Google Scholar 

  34. Parsons JT, Million RR. Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys. 1988;14(4):797–810.

    Article  CAS  PubMed  Google Scholar 

  35. Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995;32(2):331–40.

    Article  CAS  PubMed  Google Scholar 

  36. Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, el Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23(3):511–7.

    Article  CAS  PubMed  Google Scholar 

  37. Reisinger SA, Mohiuddin M, Mulholland SG. Combined pre- and postoperative adjuvant radiation therapy for bladder cancer – a ten year experience. Int J Radiat Oncol Biol Phys. 1992;24(3):463–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Melis Gultekin M.D., Sezin Yuce Sari M.D., Pervin Hurmuz M.D., Gozde Yazici M.D., Fadil Akyol M.D. & Gokhan Ozyigit M.D.

Authors
  1. Melis Gultekin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sezin Yuce Sari M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pervin Hurmuz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gozde Yazici M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fadil Akyol M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gokhan Ozyigit M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sezin Yuce Sari M.D. .

Editor information

Editors and Affiliations

  1. Chair and Professor, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit

  2. Chair and Professor, Department of Radiation Oncology, Koc University, Istanbul, Turkey

    Ugur Selek

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Gultekin, M., Sari, S.Y., Hurmuz, P., Yazici, G., Akyol, F., Ozyigit, G. (2017). Target Volume Delineation Guidelines in Bladder Cancer. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation